Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome

E-ISSN： 1875-5607|6|5|563-573

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.6, Iss.5, 2006-01, pp. : 563-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

By Miller Anne R Etgen Garret J

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1489-1500

Informa Healthcare

Access to resources Recommend Favorite

PPAR Ligands for Metabolic Disorders

Current Topics in Medicinal Chemistry, Vol. 3, Iss. 14, 2003-10 ,pp. : 1649-1661

Bentham Science Publishers

Access to resources Recommend Favorite

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

By Chan Dick C Watts Gerald F

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 13-30

Informa Healthcare

Access to resources Recommend Favorite

The Relationship between Adipokines, Metabolic Parameters and Insulin Resistance in Patients with Metabolic Syndrome and Type 2 Diabetes

By Lee JM Kim SR Yoo SJ Hong OK Son HS Chang SA

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1803-1812

Field House Publishing

Access to resources Recommend Favorite

Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

By Keating Gillian M. Croom Katherine F.

Drugs, Vol. 67, Iss. 1, 2007-01 ,pp. : 121-153

Adis International

Access to resources Recommend Favorite